

2022  
UPDATE



# A Pharmacist's Guide to Antimicrobial Stewardship in Asian Hospitals



AMR&S  
WORKING GROUP



# A Pharmacist's Guide to Antimicrobial Stewardship in Asian Hospitals

Multidisciplinary antimicrobial stewardship (AMS) teams are required to implement and manage the various interventions used as part of hospital AMS programs to promote the optimal use of antibiotics.<sup>1,2</sup> Clinical pharmacists, preferably with infectious disease (ID) pharmacotherapy residency training, are ideally suited to perform many important daily AMS tasks related to the best selection, dosing, route of administration and duration of antibiotic therapy, and should play a prominent role in AMS teams.<sup>1-6</sup>

This guide describes the daily work of the pharmacist within the AMS program, and the role of the pharmacist within the AMS team. The guide is intended to provide ideas and examples of ways to make the best use of pharmacists' expertise in AMS programs. The advice contained in this guide is consistent with evidence-based **guidelines** for the implementation of AMS programs from the Infectious Diseases Society of America (IDSA)/Society for Healthcare Epidemiology of America (SHEA)<sup>1</sup> and the American Society of Health-System Pharmacists (ASHP) **statement** on the pharmacist's role in AMS.<sup>4</sup>

The Antimicrobial Resistance & Stewardship Working Group would like to acknowledge the support from Pfizer that has made this material possible.

## Pharmacist involvement in routine AMS tasks

Pharmacists often perform routine AMS program activities (Table 1), including review of antibiotic orders for optimal antibiotic choice, dose, route of administration, duration of therapy, and providing feedback to prescribers regarding appropriateness of therapy and opportunities for intravenous (IV)-to-oral conversion and de-escalation where possible.<sup>2,5-13</sup> Pharmacists may also be responsible for monitoring and reporting AMS **key performance indicators**, such as antibiotic use and costs.<sup>5,7,14,15</sup> AMS pharmacists should ideally have protected time for AMS tasks to prevent the risk of other routine pharmacy services taking priority over AMS.<sup>5-7</sup>

**Table 1****IDSA/SHEA-recommended, evidence-based AMS interventions that can be integrated into routine pharmacy services<sup>1,16</sup>**

<b>Intervention</b>	<b>Comments</b>
<b>Core interventions</b>	One or both strategies should be included in all AMS programs
Preauthorization	<ul style="list-style-type: none"> <li>Certain antibiotics must be approved before they can be prescribed</li> </ul>
Prospective audit and feedback	<ul style="list-style-type: none"> <li>Prescriptions for audited antibiotics are reviewed after empiric antibiotic therapy has started, with direct feedback and recommendations to continue, adjust, change or discontinue therapy</li> <li>Aim to review prescriptions within 48 hours of the start of empiric therapy and again in relation to blood culture results (<math>\geq 72</math> hours)</li> </ul>
<b>Additional interventions</b>	These strategies should be a part of core interventions processes
Hospital-specific guidelines for common infectious disease syndromes	<ul style="list-style-type: none"> <li>Help to standardize prescribing practices based on local resistance patterns, evidence-based guidelines and relevant clinical factors</li> <li>Use to guide and assess empiric treatment choices, de-escalation, IV-to-oral conversion and duration of therapy</li> </ul>
De-escalation	<ul style="list-style-type: none"> <li>Review patients for opportunities to switch to narrower-spectrum antibiotics or discontinue antibiotics based on clinical criteria and culture results</li> <li>Choice of antibiotics for de-escalation during empiric therapy can be based on hospital guidelines, while that for pathogen-directed therapy is based on microbiology results</li> </ul>
IV-to-oral conversion	<ul style="list-style-type: none"> <li>Change antibiotics with good oral bioavailability from the IV to oral route as soon as possible</li> <li>Relatively simple strategy applicable to many settings</li> </ul>
Dose optimization	<ul style="list-style-type: none"> <li>Based on patient characteristics, microorganism, site of infection and pharmacodynamic/pharmacokinetic principles of antibiotic agents (consider for broad-spectrum <math>\beta</math>-lactams)</li> <li>Individualized pharmacokinetic monitoring and adjustment for IV antibiotics help ensure adequacy of treatment (consider for aminoglycosides and vancomycin at least, if not for all antibiotics; most important in critically ill patients)</li> </ul>

## Preauthorization and prospective audit

It is recommended that all AMS programs include some form of preauthorization or prospective audit, or a combination of both.<sup>1,2</sup> These core interventions can be largely pharmacist-driven.<sup>9-12</sup> For example, pharmacists are essential for the success of prospective audit and feedback as part of the AMS program at Singapore General Hospital (SGH) (Figure 1).<sup>12</sup> Pharmacists may also be responsible for assessing the appropriateness of prescriptions for antibiotics requiring preauthorization, and for contacting the prescriber when the prescription does not comply with criteria for approval.<sup>17</sup>

Antibiotics requiring preauthorization or audit are carefully selected based on variables such as:

- Broad-spectrum coverage<sup>12,18</sup>
- Potential to promote resistance<sup>12,18</sup>
- Potential for overuse or misuse<sup>12,18</sup>
- Need to reserve for the treatment of multidrug-resistant infections<sup>18</sup>
- High costs<sup>12,18</sup>
- Risk of serious adverse effects<sup>18</sup>

Carbapenems, fluoroquinolones and glycopeptides are examples of antibiotic drug classes that are often **controlled** in response to high consumption and emergence of resistance to these classes of drugs in Asian hospitals.<sup>2,10,12,15,19,20</sup> The hospital formulary should be regularly **reviewed** and updated in relation to antibiotic consumption and resistance data.<sup>21</sup>

## CASE EXAMPLE<sup>12,19,22-24</sup>

### **Pharmacist-driven prospective audit and feedback** Singapore General Hospital, Singapore

#### Pharmacist role

- Review prescriptions of audited antibiotics\* on:
  - Day 2 (empiric therapy; within 24 hours of antibiotic prescription)
  - Day 4 (allowing 72 hours for bacterial cultures to be processed)
  - Day 7 and regularly thereafter (if applicable)
- When appropriate, make written and/or verbal recommendations for:
  - IV-to-oral conversion
  - Dose optimization
  - De-escalation
- Only complicated cases are referred to an ID physician for review. See Figure 1 for workflow

#### Criteria for inappropriate prescription

- Hospital antibiotic guidelines not followed without valid reasons
- IV dose, route, duration and/or empirical treatment choice suboptimal according to hospital guidelines
- Narrower-spectrum antibiotic could be used based on culture results
- No bacterial infection (ie, colonization or alternative explanation for symptoms)


#### Measured outcomes (intervention-adherent vs non-adherent)

- Reduced audited antibiotic consumption and costs
- Shorter duration of therapy and hospital stay

\*Selection criteria: High procurement costs, broad-spectrum coverage and associated high resistance rates, potential for misuse, increasing trends of prescription.

**Figure 1**

**Workflow of the pharmacist-driven prospective audit and immediate feedback system as part of the AMS program at Singapore General Hospital<sup>12,19,23,24</sup>**



Adapted from Teo J, et al. 2012; Liew YX, et al. 2012; and Loo LW, et al. 2015.

As is the case at SGH,<sup>12,24</sup> the following AMS tools and strategies are commonly integrated into the pharmacist's antibiotic review process:

- Hospital-specific antibiotic guidelines
- De-escalation
- IV-to-oral conversion
- Dose optimization

## Hospital-specific antibiotic guidelines

When they are available, hospital-specific antibiotic treatment **guidelines** should be used by pharmacists as a benchmark to assess the appropriateness of therapy, including antibiotic choice and duration of therapy, and make empiric recommendations for therapy change.<sup>8,24-26</sup>

Hospital-specific guidelines can be adapted from general evidence-based practice guidelines from professional societies such as the **IDSA** to suit the hospital formulary and bacterial susceptibility patterns seen on the hospital **antibiogram**.<sup>24,25</sup> Such guidelines usually contain antibiotic recommendations and other helpful advice for commonly treated infections, including but not limited to:

- Community-acquired pneumonia
- Hospital- and ventilator-acquired pneumonia
- Skin and soft tissue infections
- Urinary tract infections
- Intra-abdominal infections
- Sepsis

### Empiric vs definitive antibiotic therapy<sup>27,28</sup>

- In the absence of rapid diagnostic testing, which may be cost prohibitive, microbiology results are generally not available for 24 to 72 hours
- Initial antibiotic therapy is, therefore, usually empiric and guided by clinical presentation and the organisms most likely to be causing the infection at that site of infection
- When the pathogen causing the infection is identified, definitive pathogen-directed antibiotic therapy can be started



## De-escalation

If the hospital's empiric antibiotic treatment guidelines have not been followed without a valid reason, the pharmacist should recommend that broad-spectrum empiric therapy be de-escalated in clinically stable patients (Table 2).<sup>8,29</sup> For example, carbapenem therapy can be de-escalated in Asian settings where ESBL-producing Gram-negative organisms are endemic.<sup>8</sup> Choice of antibiotics during empirical therapy should be based on hospital guidelines, and tailored to patient characteristics, site of infection, risk factors for multidrug-resistant bacteria, and local microbiology and susceptibility patterns.<sup>8,26</sup> Once microbiology results are available, the pharmacist should encourage the change to definitive therapy with as narrow a spectrum pathogen-directed treatment as possible based on culture and susceptibility results.<sup>8,26,27,29</sup>

## CASE EXAMPLE<sup>8</sup>

### Pharmacist-driven carbapenem de-escalation

Tan Tock Seng Hospital, Singapore

#### Pharmacist role

- Review carbapenem prescriptions on:
  - Days 1 and 2 for appropriate indications and dosage based on evidence-based, hospital-approved guidelines
  - Day 3 onwards for a de-escalation opportunity
- Recommendations for de-escalation where appropriate (Table 2) documented in the patient's chart, including reasons for de-escalation, often with telephone or face-to-face discussions
- Only complicated cases or cases where the primary care team does not accept the ward pharmacist's recommendations are referred to ID physicians for review

#### Choice of antibiotic for de-escalation

- Hospital antibiotic guidelines for empiric therapy
- Culture and susceptibility results for definitive pathogen-directed therapy

#### Measured outcomes (de-escalated vs not de-escalated)

- Shorter duration of therapy
- Lower rate of adverse drug reactions
- Lower incidence of carbapenem-resistant *Acinetobacter baumannii* acquisition
- Lower incidence of *Clostridium difficile*-associated diarrhea

**Table 2**

**Criteria for the de-escalation of broad-spectrum antibiotics used by pharmacists during prospective audit and feedback as part of an AMS program at Tan Tock Seng Hospital, Singapore<sup>8</sup>**


	<b>Empiric therapy</b>	<b>Definitive therapy</b>
Criteria for de-escalation via switching to narrower-spectrum antibiotics	<ul style="list-style-type: none"><li>• Temperature &lt;38°C for 24 hours</li><li>• Not on inotropes</li><li>• Systolic blood pressure returned to baseline or <math>\geq 100</math> mmHg</li><li>• Not mechanically ventilated or fraction of inspired oxygen <math>\leq 0.4</math></li><li>• Respiratory rate &lt;25 breaths per minute and saturation of oxygen <math>\geq 92\%</math> on room air</li></ul>	<ul style="list-style-type: none"><li>• De-escalation to narrower-spectrum antibiotics based on culture and susceptibility results, in the absence of contraindications</li></ul>
Criteria for de-escalation via discontinuation	<ul style="list-style-type: none"><li>• Completed course of therapy</li><li>• No indication or infectious causes identified</li></ul>	

### IV-to-oral conversion

IV-to-oral conversion of the same antibiotic is a relatively simple intervention, and pharmacists should routinely encourage IV-to-oral conversion of antibiotics with good bioavailability in eligible patients (Figure 2).<sup>1,2,13,26</sup> For example, fluoroquinolones are highly bioavailable drugs that can easily be converted from the IV to the oral route of administration.<sup>30</sup> Advantages of oral therapy include ease of administration, early discharge opportunities, decreased IV-related adverse events and drug cost savings.<sup>26</sup>

**Figure 2**

**The IV-to-oral conversion guideline used by pharmacists during prospective audit as part of the AMS program at Singapore General Hospital<sup>12</sup>**



Adapted from Teo J, et al. 2012.

## CASE EXAMPLE<sup>30</sup>

### **Pharmacist-driven IV-to-oral conversion of fluoroquinolones**

Seoul National University Bundang Hospital, Korea

#### **Pharmacist role**

- Identify patients in general wards receiving IV fluoroquinolones for  $\geq 3$  days who are able to take oral medication
- Recommend IV-to-oral conversion via a note in the medical record stating:
  - Primary site of infection
  - Purpose of antibiotic administration
  - Type of fluoroquinolone being administered, dose and treatment period
  - Information on oral equivalent dose and drug interactions

#### **Measured outcomes (switched vs not switched)**

- Shorter duration of IV and total fluoroquinolone therapy
- Shorter duration of hospital stay
- Lower IV and total fluoroquinolone costs

## Dose optimization

Pharmacist expertise in relation to pharmacokinetic and pharmacodynamic principles is particularly beneficial when reviewing antibiotic regimens for dose optimization.<sup>2,31</sup> Dose optimization may not necessarily require therapeutic drug monitoring, and can be implemented by pharmacists on the basis of identifying deviations from recommended dosing schedules, and making recommendations to optimize dosing based on pharmacokinetic and pharmacodynamic principles.<sup>2,12</sup> However, in critically ill patients, dose optimization via therapeutic drug monitoring will help ensure adequacy of treatment.<sup>2,32</sup>

## The pharmacist as part of the AMS team leadership structure


It is recommended that a clinical pharmacist, preferably with ID pharmacotherapy residency training, co-lead the AMS team with an ID physician team leader (Figure 3).<sup>1,2</sup> The pharmacist co-leader should support the team leader in their tasks, including:

- The development and maintenance of treatment **guidelines**
- Antibiotic audit and formulary choices
- Providing AMS advice and education to relevant hospital staff

In hospitals where there are no available ID physicians, a clinical pharmacist, preferably with ID pharmacotherapy residency training, may be called on to **lead** the team.<sup>2</sup> In such a setting, the pharmacist is required to **implement** and **sustain** the AMS program.<sup>33</sup>

**Figure 3**

## **Suggested hospital AMS team structure and function<sup>2,3,16</sup>**



Adapted from Apisarnthanarak, et al. 2018; Dellit, et al. 2007; and the Centers for Disease Control and Prevention 2019.

## CASE EXAMPLE<sup>33</sup>

### A pharmacist-led AMS program

McKay-Dee Hospital, United States

#### Setting

- Small community hospital with no ID physician for routine consult
- Easily applied to Asian hospitals with little or no ID physician support

#### Pharmacist background

- Strong interest and background in ID practice
- No formal post-graduate ID training

#### Pharmacist role

- 0.9 full-time equivalent
- 6-month pre-implementation lead-in for educational and promotional strategies:
  - Presentations at medical staff meetings
  - Discussions with physicians about perceptions of a pharmacist-led AMS program
  - Education of pharmacy staff regarding the new program and ideas for implementation
  - E-mails to medical staff with updates on implementation of the program
- Routine tasks:
  - Manually review all patients receiving antibiotics with face-to-face discussions with prescribers to make recommendations for:
    - » De-escalation
    - » IV-to-oral conversion
    - » Dose optimization
  - Available by phone to answer after-hours questions relating to antibiotic therapy



- Provide formal and informal education about optimal antibiotic use to hospital staff
- Regularly meet with pharmacy and medical directors, and a hospitalist and intensivist, to receive feedback on how the program could be improved
- Send monthly reports to the pharmacy director and hospital administration detailing interventions made, cost savings, program successes and areas for improvement

### Measured outcomes (year before implementation vs after implementation)

- Reduced use of targeted antibiotics, such as carbapenems
- Reduced length of hospital stay for patients with community-acquired pneumonia
- Reduced antibiotic costs

### ID training for AMS pharmacists

It is recommended that an AMS pharmacist should ideally have some ID training.<sup>2</sup> If ID-trained pharmacists are unavailable, clinical pharmacists with an interest in but no formal ID training could serve as core AMS team members and take on AMS activities.<sup>2,34</sup> A potential strategy could be to initially have pharmacists with no ID training assist with AMS interventions that require less ID expertise, such as IV-to-oral conversion.<sup>13,34</sup> Non-ID pharmacists in the AMS team could acquire ID knowledge and skills by shadowing pharmacist, physician or microbiology experts; reading key guidelines and articles; attending professional ID conferences; or completing AMS training programs.<sup>34</sup> Furthermore, ID training courses for AMS pharmacists can be established within the hospital.<sup>35</sup>

## CASE EXAMPLE<sup>35,36</sup>

### **ID training for clinical pharmacists, and ID pharmacist-enhanced and -led interventions**

Thammasat University Hospital, Thailand

#### **Hospital-based pharmacist ID training<sup>35</sup>**

- Six 2-hour ID training sessions
- Seven topics:
  1. Definition of appropriate antibiotic use
  2. Common antibiotic drug interactions
  3. Antibiotic de-escalation
  4. Monitoring antibiotic side effects
  5. Structure and organization of the AMS program
  6. Monitoring AMS program outcomes
  7. Examples of antibiotic use recommendations provided by an experienced ID physician
- After the training program, hospital-wide adjunct ID clinical pharmacist consultation was made available<sup>35</sup>
- A pharmacist-led intervention was subsequently studied<sup>36</sup>

#### **Pharmacist role in a pharmacist-enhanced AMS program<sup>35</sup>**

After an ID clinical pharmacist consultation request, the ID clinical pharmacist was responsible for:

- Participation in daily rounds with the medical team
- Advice on antibiotic use and potential adverse events
- De-escalation reminders

#### **Measured outcomes (ID clinical pharmacist-enhanced consultation vs standard of care)<sup>35</sup>**

- More appropriate antibiotic use
- More de-escalation
- Shorter treatment duration
- Shorter length of hospital stay

### Pharmacist-led intervention<sup>36</sup>

- The ID pharmacist routinely performed daily prospective audit and feedback along with bedside discussion
  - Suitable antibiotics were suggested for each patient, with appropriate dose and recommended treatment duration
  - The pharmacist then followed the patient until discharge
  - Additional ID physician consultations requested if inappropriate antimicrobial prescriptions were noted
- Other ID pharmacist tasks:
  - Provision of continuous education regarding appropriate antimicrobial therapy
  - Provision of feedback regarding antimicrobial consumption to nurses and physicians involved in antimicrobial therapy
  - Monitoring patients for guideline adherence every 2 weeks (appropriate indication, dose regimen and duration)

### Measured outcomes (ID pharmacist-led intervention vs standard AMS program protocol)<sup>36</sup>

- Higher AMS program guideline adherence for empirical and definitive therapy
- Reduced carbapenem and fosfomycin consumption
- Decreased incidence of multidrug-resistant pathogens
- Trend toward increased rate of clinical cure
- Similar 30-day all-cause mortality and length of stay

Non-ID pharmacists can easily make individual efforts to improve their knowledge of ID- and AMS-related issues.<sup>5,34</sup> This may be achieved by a variety of methods such as:

- Becoming familiar with key evidence-based ID clinical practice guidelines, most of which are available on the IDSA website ([www.idsociety.org/practice-guideline/alphabetical-guidelines/](http://www.idsociety.org/practice-guideline/alphabetical-guidelines/))
- Making use of educational resources, such as those provided by the ASHP ([www.ashp.org](http://www.ashp.org)), Centers for Disease Control and Prevention ([www.cdc.gov/antibiotic-use/healthcare/index.html](http://www.cdc.gov/antibiotic-use/healthcare/index.html)), Society of Infectious Diseases Pharmacists ([www.sidp.org/AMSToolkit](http://www.sidp.org/AMSToolkit)) and Center for Infectious Disease Research and Policy ([www.cidrap.umn.edu/asp](http://www.cidrap.umn.edu/asp))
- Attending rounds with an ID physician
- Visiting institutions with existing AMS programs, such as SGH which offers a clinical attachment in ID pharmacotherapy for hospital pharmacists (more information can be found at: [www.sgh.com.sg/pgahi/attachments/Pages/Pharmacy.aspx](http://www.sgh.com.sg/pgahi/attachments/Pages/Pharmacy.aspx))
- Completing a certification program for pharmacists, such as that provided by the Society of Infectious Diseases Pharmacists (more information can be found at: [www.sidp.org/Stewardship-Certificate](http://www.sidp.org/Stewardship-Certificate))

# Summary

Pharmacists are core members of multidisciplinary AMS teams. The success of AMS programs in Asian hospitals relies on the day-to-day efforts of dedicated pharmacists with and without formal post-graduate ID training. Ideally, AMS should be a collaborative partnership between pharmacists and physicians, with support from other AMS team members.

# References

1. Barlam TF, et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis* 2016;62:e51-77.
2. Apisarnthanarak A, et al. Antimicrobial stewardship for acute-care hospitals: An Asian perspective. *Infect Control Hosp Epidemiol* 2018;39:1237-1245.
3. CDC. The Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at [www.cdc.gov/antibiotic-use/core-elements/hospital.html](http://www.cdc.gov/antibiotic-use/core-elements/hospital.html). Accessed July 2022.
4. American Society of Health-System Pharmacists. ASHP statement on the pharmacist's role in antimicrobial stewardship and infection prevention and control. *Am J Health Syst Pharm* 2010;67:575-577.
5. Parente DM and Morton J. Role of the pharmacist in antimicrobial stewardship. *Med Clin North Am* 2018;102:929-936.
6. Wong LH, et al. Hospital pharmacists and antimicrobial stewardship: A qualitative analysis. *Antibiotics (Basel)* 2021;10:1441.
7. Lai WM, et al. Pharmacists' perspectives of their roles in antimicrobial stewardship: A qualitative study among hospital pharmacists in Malaysia. *Antibiotics (Basel)* 2022;11:219.
8. Lew KY, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. *J Antimicrob Chemother* 2015;70:1219-1225.
9. Li Z, et al. Pharmacist-driven antimicrobial stewardship in intensive care units in East China: A multicenter prospective cohort study. *Am J Infect Control* 2017;45:983-989.
10. Ohashi K, et al. Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics. *Eur J Clin Microbiol infect Dis* 2019;38:593-600.

11. Sing DYF, et al. Antimicrobial stewardship program in a Malaysian district hospital: First year experience. *Pak J Med Sci* 2016;32:999-1004.
12. Teo J, et al. The effect of a whole-system approach in an antimicrobial stewardship programme at the Singapore General Hospital. *Eur J Clin Microbiol Infect Dis* 2012;31:947-955.
13. Xu S, et al. Impact and barriers of a pharmacist-led practice with computerized reminders on intravenous to oral antibiotic conversion for community-acquired pneumonia inpatients. *J Clin Pharm Ther* 2021;46:1055-1061.
14. Chang YY, et al. Implementation and outcomes of an antimicrobial stewardship program: Effectiveness of education. *J Chin Med Assoc* 2017; 80:353-359.
15. Wang HY, et al. Blood culture-guided de-escalation of empirical antimicrobial regimen for critical patients in an online antimicrobial stewardship programme. *Int J Antimicrob Agents* 2014;44:520-527.
16. Dellit TH, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis* 2007;44:159-177.
17. Public Health Ontario. Antimicrobial stewardship strategy: Formulary restriction with preauthorization. Available at: [www.publichealthontario.ca/apps/asp-strategies/data/pdf/ASP\\_Strategy\\_Formulary\\_Restriction\\_Preauthorization.pdf](http://www.publichealthontario.ca/apps/asp-strategies/data/pdf/ASP_Strategy_Formulary_Restriction_Preauthorization.pdf). Accessed July 2022.
18. Public Health Ontario. Antimicrobial stewardship strategy: Formulary restriction. Available at: [www.publichealthontario.ca/apps/asp-strategies/data/pdf/ASP\\_Strategy\\_Formulary\\_Restriction.pdf](http://www.publichealthontario.ca/apps/asp-strategies/data/pdf/ASP_Strategy_Formulary_Restriction.pdf). Accessed July 2022.
19. Liew YX, et al. Impact of an antimicrobial stewardship programme on patient safety in Singapore General Hospital. *Int J Antimicrob Agents* 2012;40:55-60.

20. Cheon S, et al. Controlling endemic multidrug-resistant *Acinetobacter baumannii* in Intensive Care Units using antimicrobial stewardship and infection control. *Korean J Intern Med* 2016;31:367-374.
21. Public Health Ontario. Antimicrobial stewardship strategy: Formulary review/streamlining. Available at: [www.publichealthontario.ca/apps/asp-strategies/data/pdf/ASP\\_Strategy\\_Formulary\\_Review.pdf](http://www.publichealthontario.ca/apps/asp-strategies/data/pdf/ASP_Strategy_Formulary_Review.pdf). Accessed July 2022.
22. Liew YX, et al. Cost effectiveness of an antimicrobial stewardship programme. *Int J Antimicrob Agents* 2015;46:594-595.
23. Loo LW, et al. Impact of antimicrobial stewardship program (ASP) on outcomes in patients with acute bacterial skin and skin structure infections (ABSSSIs) in an acute-tertiary care hospital. *Infect Dis Ther* 2015;4(Suppl 1):15-25.
24. Loo LW, et al. Discontinuation of antibiotic therapy within 24 hours of treatment initiation for patients with no clinical evidence of bacterial infection: a 5-year safety and outcome study from Singapore General Hospital Antimicrobial Stewardship Program. *Int J Antimicrob Agents* 2019;53:606-611.
25. Kalil AC, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 2016;63:e61-e111.
26. Levy Hara G, et al. Ten key points for the appropriate use of antibiotics in hospitalised patients: a consensus from the Antimicrobial Stewardship and Resistance Working Groups of the International Society of Chemotherapy. *Int J Antimicrob Agents* 2016;48:239-246.
27. Leekha S, et al. General Principles of Antimicrobial Therapy. *Mayo Clin Proc* 2011;86:156-167.
28. Apisarnthanarak A, et al. Rapid diagnostic testing for antimicrobial stewardship: Utility in Asia Pacific. *Infect Control Hosp Epidemiol* 2021;42:864-868.



29. Liew YX, et al. Prospective audit and feedback in antimicrobial stewardship: Is there value in early reviewing within 48 h of antibiotic prescription? *Int J Antimicrob Agents* 2015;45:168-173.
30. Park SM, et al. Impact of intervention by an antimicrobial stewardship team on conversion from intravenous to oral fluoroquinolones. *Infect Chemother* 2017;49:31-37.
31. Doron S, Davidson L. Antimicrobial stewardship. *Mayo Clin Proc* 2011;86:1113-1123.
32. Cotta MO, et al. Antibiotic dose optimization in critically ill patients. *Med Intensiva* 2015;39:563-572.
33. Waters CD. Pharmacist-driven antimicrobial stewardship program in an institution without infectious diseases physician support. *Am J Health Syst Pharm* 2015;72:466-468.
34. Patel D, MacDougall C. How to make antimicrobial stewardship work: Practical considerations for hospitals of all sizes. *Hosp Pharm* 2010;45(11 Suppl 1):S10-S18.
35. Apisarnthanarak A, et al. Design and analysis of a pharmacist-enhanced antimicrobial stewardship program in Thailand. *Am J Infect Control* 2015;43:956-959.
36. Jantarathaneewat K, et al. Impact of an infectious diseases pharmacist-led intervention on antimicrobial stewardship program guideline adherence at a Thai medical center. *Am J Health Syst Pharm* 2022;79:1266-1272.



**AMR&S**  
WORKING GROUP